NASDAQ$IRWD
Ironwood Pharmaceuticals Inc. · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter results with LINZESS prescription demand growth and progress on apraglutide NDA submission.
Ironwood Pharmaceuticals reported its third quarter 2024 results, highlighting a 13% year-over-year growth in LINZESS prescription demand. The company is maintaining its full year financial guidance and is on track to complete the apraglutide NDA submission in Q1 2025.
- LINZESS prescription demand grew by 13% year-over-year.
- LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year.
- The company remains on track to complete apraglutide NDA submission in Q1 2025.
- Full year 2024 financial guidance is maintained despite pricing headwinds.
Headline financials
Revenue & EPS history
Ironwood Pharmaceuticals · Revenue · Quarterly
$91.6M
Revenue by segment
Ironwood Pharmaceuticals · $71M total across 1 segment · Q1 2020
- LINZESS Collaboration$71M—100.0%
Forward guidance
Ironwood Pharmaceuticals is maintaining its full year 2024 financial guidance and expects to complete the apraglutide NDA submission in the first quarter of 2025.
Tailwinds
- Continued growth in LINZESS prescription demand.
- On track to complete apraglutide NDA submission in Q1 2025.
- Focus on getting apraglutide to market as soon as possible.
- Belief that apraglutide would be the drug of choice for SBS patients dependent on PS, if approved.
- Maintaining full year financial guidance.
Headwinds
- LINZESS faced pricing headwinds throughout 2024.
- Uncertainty related to pricing and reimbursement policies in the U.S.
- Risk of competition from new products.
- Challenges in partnering with other companies to develop and commercialize products.
- Potential adverse effects from healthcare reform and other governmental and private payor initiatives.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.0%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-1.2%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+32.8%
Q3 2025
Best reaction
-29.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.9% | -15.5% | -31.5% | |
| Q4 2025 | -11.4% | -5.8% | -19.3% | |
| Q3 2025 | +32.8% | +63.5% | +92.2% | |
| Q1 2025 | -4.4% | +0.0% | +5.1% | |
| Q4 2024 | -5.3% | -12.9% | -17.5% | |
| Q3 2024 | -1.6% | -12.9% | -31.9% | |
| Q2 2024 | -29.5% | -25.3% | -25.0% | |
| Q1 2024 | -13.8% | -18.3% | -21.8% | |
| Q4 2023 | -5.6% | -4.0% | -41.6% | |
| Q3 2023 | +5.5% | +5.6% | +13.5% | |
| Q2 2023 | -15.3% | -11.3% | -24.2% | |
| Q1 2023 | +1.5% | -2.4% | +4.9% | |
| Q4 2022 | +5.8% | +3.9% | -7.4% | |
| Q3 2022 | +3.7% | +6.8% | +11.9% | |
| Q2 2022 | +5.9% | +5.6% | -2.9% | |
| Q1 2022 | -3.0% | -8.4% | -9.0% | |
| Q4 2021 | -2.5% | -1.2% | +13.5% | |
| Q3 2021 | +0.4% | -1.2% | -14.6% | |
| Q2 2021 | +3.2% | +4.3% | -1.5% | |
| Q1 2021 | +1.3% | +1.5% | +9.3% | |
| Q4 2020 | -7.0% | -6.6% | +12.3% | |
| Q3 2020 | +4.0% | +12.4% | +16.8% | |
| Q2 2020 | +5.8% | +3.0% | +1.5% | |
| Q1 2020 | -3.2% | +2.5% | -5.3% | |
| Q4 2019 | -3.2% | -2.9% | -18.3% | |
| Q3 2019 | +10.0% | +15.9% | +27.5% | |
| Q2 2019 | +2.6% | -0.8% | -10.0% | |
| Q1 2019 | -9.9% | -12.3% | -7.2% | |
| Q4 2018 | +5.4% | +15.1% | +3.1% | |
| Q3 2018 | -15.6% | -15.9% | -10.3% | |
| Q2 2018 | -1.1% | -1.9% | -1.1% | |
| Q1 2018 | +4.4% | +2.6% | +2.5% | |
| Q4 2017 | +6.0% | +2.4% | +6.0% | |
| Q3 2017 | +6.8% | +1.8% | +16.6% | |
| Q2 2017 | -12.8% | -15.5% | -9.0% | |
| Q1 2017 | +5.2% | +12.9% | +10.5% | |
| Q4 2016 | -1.6% | -4.2% | +0.1% | |
| Q3 2016 | +7.2% | +15.2% | +22.5% | |
| Q2 2016 | -6.0% | -7.7% | -6.9% | |
| Q1 2016 | +9.3% | — | — | |
| Q4 2015 | +3.4% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | -0.1% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | -4.0% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | -8.9% | — | — | |
| Q4 2012 | -7.7% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.8% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q1 2012 | -3.5% | — | — | |
| Q4 2011 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q3 2011 | -13.6% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q1 2010 | -3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro